Lometrexol
Based on 7 publication(s) in Google Scholar
Lometrexol (DDATHF), an antipurine antifolate, can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol can further inhibit de novo purine synthesis, causing abnormal cell proliferation and apoptosis, even cell cycle arrest. Lometrexol has anticancer activity. Lometrexol also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) inhibitor.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.44%
- CAS. Nr.: 106400-81-1
- Formel: C21H25N5O6
- Molecular Weight:443.45
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Lometrexol
More-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
Alle Caspase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCRF-CEM | IC50 |
>100 μM
Compound: Lometrexol
|
Cytotoxicity in the absence of thymidine and presence of hypoxanthine against CCRF-CEM cell line
Cytotoxicity in the absence of thymidine and presence of hypoxanthine against CCRF-CEM cell line
|
[PMID: 10888335] |
| CCRF-CEM | IC50 |
>100 μM
Compound: Lometrexol
|
Cytotoxicity in the presence of thymidine and hypoxanthine against CCRF-CEM cell line
Cytotoxicity in the presence of thymidine and hypoxanthine against CCRF-CEM cell line
|
[PMID: 10888335] |
| CCRF-CEM | IC50 |
0.07 μM
Compound: Lometrexol
|
Cytotoxicity in the absence of hypoxanthine and presence of thymidine against CCRF-CEM cell line
Cytotoxicity in the absence of hypoxanthine and presence of thymidine against CCRF-CEM cell line
|
[PMID: 10888335] |
| CCRF-CEM | IC50 |
0.13 μM
Compound: Lometrexol
|
Cytotoxicity in the absence of thymidine and hypoxanthine against CCRF-CEM cell line
Cytotoxicity in the absence of thymidine and hypoxanthine against CCRF-CEM cell line
|
[PMID: 10888335] |
| CCRF-CEM | IC50 |
0.016 μM
Compound: DDATHF
|
Cytotoxicity against human lymphoblastic leukemic CCRF-CEM cell line was evaluated as the concentration required for 50% inhibition of the growth of the control value
Cytotoxicity against human lymphoblastic leukemic CCRF-CEM cell line was evaluated as the concentration required for 50% inhibition of the growth of the control value
|
[PMID: 1552503] |
| CCRF-CEM | IC50 |
>100 μM
Compound: lometrexol
|
Antiproliferative activity against human CCRF-CEM cell line in presence of hypoxanthine
Antiproliferative activity against human CCRF-CEM cell line in presence of hypoxanthine
|
[PMID: 16686541] |
| CCRF-CEM | IC50 |
0.2 μM
Compound: lometrexol
|
Antiproliferative activity against human CCRF-CEM cell line
Antiproliferative activity against human CCRF-CEM cell line
|
[PMID: 16686541] |
| CCRF-CEM | IC50 |
0.2 μM
Compound: lometrexol
|
Antiproliferative activity against human CCRF-CEM cell line in presence of thymidine
Antiproliferative activity against human CCRF-CEM cell line in presence of thymidine
|
[PMID: 16686541] |
| CCRF-CEM | IC50 |
25 μM
Compound: lometrexol
|
Antiproliferative activity against FPGS-deficient CCRF-CEM cell line
Antiproliferative activity against FPGS-deficient CCRF-CEM cell line
|
[PMID: 16686541] |
| CCRF-CEM | IC50 |
>10 μM
Compound: lometrexol, (6R)-5,10-DDATHF
|
Cytotoxicity against folyl-poly-glutamate synthetase-deficient human CCRF-CEM cells in absence of thymidine and hypoxanthine
Cytotoxicity against folyl-poly-glutamate synthetase-deficient human CCRF-CEM cells in absence of thymidine and hypoxanthine
|
[PMID: 18686942] |
| CCRF-CEM | IC50 |
>10 μM
Compound: lometrexol, (6R)-5,10-DDATHF
|
Cytotoxicity against human CCRF-CEM cells in absence of thymidine and presence of hypoxanthine
Cytotoxicity against human CCRF-CEM cells in absence of thymidine and presence of hypoxanthine
|
[PMID: 18686942] |
| CCRF-CEM | IC50 |
>100 μM
Compound: lometrexol, (6R)-5,10-DDATHF
|
Cytotoxicity against human CCRF-CEM cells expressing reduced folate carrier in absence of thymidine and hypoxanthine
Cytotoxicity against human CCRF-CEM cells expressing reduced folate carrier in absence of thymidine and hypoxanthine
|
[PMID: 18686942] |
| CCRF-CEM | IC50 |
0.2 μM
Compound: lometrexol, (6R)-5,10-DDATHF
|
Cytotoxicity against human CCRF-CEM cells in absence of thymidine and hypoxanthine
Cytotoxicity against human CCRF-CEM cells in absence of thymidine and hypoxanthine
|
[PMID: 18686942] |
| CCRF-CEM | IC50 |
0.2 μM
Compound: lometrexol, (6R)-5,10-DDATHF
|
Cytotoxicity against human CCRF-CEM cells in presence of thymidine and absence of hypoxanthine
Cytotoxicity against human CCRF-CEM cells in presence of thymidine and absence of hypoxanthine
|
[PMID: 18686942] |
| CCRF-CEM | IC50 |
0.007 μg/mL
Compound: 1 (DDATHF)
|
The compound was tested for its cytotoxicity against CCRF-CEM human leukemic cells using 72 hrs assay
The compound was tested for its cytotoxicity against CCRF-CEM human leukemic cells using 72 hrs assay
|
10.1016/S0960-894X(01)80214-6 |
| CCRF-CEM | IC50 |
0.007 μg/mL
Compound: DDATHF
|
Tested for the growth inhibition of CCRF-CEM, a human T-cell derived lymphoblastic leukemic cell line
Tested for the growth inhibition of CCRF-CEM, a human T-cell derived lymphoblastic leukemic cell line
|
10.1016/S0960-894X(01)80736-8 |
| CCRF-CEM | IC50 |
15.2 nM
Compound: LTX (2)
|
Tested in vitro for cellular cytotoxicity against human T-cell derived lymphoblastic leukemia (CCRF-CEM) cells
Tested in vitro for cellular cytotoxicity against human T-cell derived lymphoblastic leukemia (CCRF-CEM) cells
|
10.1016/S0960-894X(97)00041-3 |
| IGROV-1 | IC50 |
16 nM
Compound: lometrexol
|
Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells in presence of folic acid
Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells in presence of folic acid
|
[PMID: 18680275] |
| IGROV-1 | IC50 |
3.1 nM
Compound: lometrexol
|
Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells
Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells
|
[PMID: 18680275] |
| IGROV-1 | IC50 |
16 nM
Compound: LMTX, Lometrexol, 6-(R)DDATHF
|
Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid
Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid
|
[PMID: 21879757] |
| IGROV-1 | IC50 |
3.1 nM
Compound: LMTX, Lometrexol, 6-(R)DDATHF
|
Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs
Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs
|
[PMID: 21879757] |
| IGROV-1 | IC50 |
5.77 nM
Compound: LMTX
|
Inhibition of GARFTase in human IGROV1 cells assessed as reduction in [14C]glycine incorporation into [14C]formyl GAR incubated for 15 hrs in complete folate free RPMI medium in presence of 2 nM leucovorin
Inhibition of GARFTase in human IGROV1 cells assessed as reduction in [14C]glycine incorporation into [14C]formyl GAR incubated for 15 hrs in complete folate free RPMI medium in presence of 2 nM leucovorin
|
[PMID: 22243528] |
| KB | IC50 |
1.2 nM
Compound: lometrexol
|
Antiproliferative activity against human RFC and FRalpha expressing human KB cells
Antiproliferative activity against human RFC and FRalpha expressing human KB cells
|
[PMID: 18680275] |
| KB | IC50 |
14 nM
Compound: lometrexol
|
Inhibition of GARFTase in human KB cells assessed as inhibition of [14C]glycine incorporation into [14C]formylGAR in presence of azaserine
Inhibition of GARFTase in human KB cells assessed as inhibition of [14C]glycine incorporation into [14C]formylGAR in presence of azaserine
|
[PMID: 18680275] |
| KB | IC50 |
31 nM
Compound: lometrexol
|
Antiproliferative activity against human RFC and FRalpha expressing human KB cells in presence of folic acid
Antiproliferative activity against human RFC and FRalpha expressing human KB cells in presence of folic acid
|
[PMID: 18680275] |
| KB | IC50 |
14 nM
Compound: LMX
|
Inhibition of GARFTase in human KB cells assessed as inhibition of incorporation of [14C]glycine into [14C]formyl GAR after 30 mins in presence of azaserine
Inhibition of GARFTase in human KB cells assessed as inhibition of incorporation of [14C]glycine into [14C]formyl GAR after 30 mins in presence of azaserine
|
[PMID: 19371039] |
| KB | IC50 |
14 μM
Compound: LMTX, (R)-6-DDATHF
|
Inhibition of GARFtase in human KB cells assessed as [14C]glycine incorporation in to [14C]FGAR in folate free RPMI medium with 2 nM LCV by in-situassay
Inhibition of GARFtase in human KB cells assessed as [14C]glycine incorporation in to [14C]FGAR in folate free RPMI medium with 2 nM LCV by in-situassay
|
[PMID: 20085328] |
| KB | IC50 |
1.2 nM
Compound: LMTX, Lometrexol, 6-(R)DDATHF
|
Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs
Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs
|
[PMID: 21879757] |
| KB | IC50 |
31 nM
Compound: LMTX, Lometrexol, 6-(R)DDATHF
|
Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid
Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid
|
[PMID: 21879757] |
| KB | IC50 |
1.2 nM
Compound: LMTX, Lometrexol
|
Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay
Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay
|
[PMID: 24111942] |
| KB | IC50 |
31 nM
Compound: LMTX, Lometrexol
|
Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay in presence of folic acid
Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay in presence of folic acid
|
[PMID: 24111942] |
| MCF7 | IC50 |
18 μM
Compound: 1
|
Ability to inhibit growth of MCF-7 human breast adenocarcinoma in vitro
Ability to inhibit growth of MCF-7 human breast adenocarcinoma in vitro
|
[PMID: 8027993] |
| MOLT-4 | IC50 |
1.5 μM
Compound: 1
|
Ability to inhibit [3H]methotrexate transport into MOLT-4 cells in vitro
Ability to inhibit [3H]methotrexate transport into MOLT-4 cells in vitro
|
[PMID: 8027993] |
| R2 | IC50 |
>1000 nM
Compound: lometrexol
|
Antiproliferative activity against human RFC expressing Chinese hamster R2 cells
Antiproliferative activity against human RFC expressing Chinese hamster R2 cells
|
[PMID: 18680275] |
| R2 | IC50 |
29.7 nM
Compound: LMTX, Lometrexol, 6-(R)DDATHF
|
Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as inhibition of colony formation after 10 to 14 days
Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as inhibition of colony formation after 10 to 14 days
|
[PMID: 21879757] |
| R2 | IC50 |
38 nM
Compound: LMTX, Lometrexol, 6-(R)DDATHF
|
Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as reduction of viable cells after 96 hrs
Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as reduction of viable cells after 96 hrs
|
[PMID: 21879757] |
| R2 | IC50 |
>1000 nM
Compound: LMTX, Lometrexol, 6-(R)DDATHF
|
Antiproliferative activity against chinese hamster R2 cells assessed as reduction of viable cells after 96 hrs
Antiproliferative activity against chinese hamster R2 cells assessed as reduction of viable cells after 96 hrs
|
[PMID: 21879757] |
| R2 | IC50 |
38 nM
Compound: LMTX, Lometrexol
|
Growth inhibition of Chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTiter-blue assay
Growth inhibition of Chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTiter-blue assay
|
[PMID: 24111942] |
| R2 | IC50 |
38 nM
Compound: LMTX, lometrexol
|
Cytotoxicity against chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTitre-Blue fluorescence assay
Cytotoxicity against chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTitre-Blue fluorescence assay
|
[PMID: 24256410] |
| R2 | IC50 |
12 nM
Compound: LMTX; (6R)-5,10-dideazatetrahydrofolate
|
Cytotoxicity in RFC-null Chinese hamster R2 cells assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue fluorescence analysis
Cytotoxicity in RFC-null Chinese hamster R2 cells assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue fluorescence analysis
|
[PMID: 27458733] |
In Vitro
Lometrexol (DDATHF) binds tightly to GART, resulting in a rapid and prolonged depletion of intracellular purine ribonucleotides[3].
Lometrexol (1-30 μM; 2-10 hours) induces rapid and complete growth inhibition in L1210 cells[3].
Lometrexol (1 μM; 2-24 hours) induces cell cycle arrest in murine leukemia L1210 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Mouse leukemia L1210 cells
-
Concentration:1, 30 μM
-
Incubation Time:2, 4, 6, 8, 10 hours
-
Result:Induced rapid and complete growth inhibition.
-
Cell Line:L1210 cells
-
Concentration:1 μM
-
Incubation Time:2, 4, 8, 12, 24 hours
-
Result:Caused a rapid loss of the G2/M phase population of cells and an early S phase accumulation of cells by 8 hours. By 24 h, the S phase population appeared to be slowly shifting to higher DNA content, and hence, from mid-to-late S phase.
In Vivo
Lometrexol (i.p.; 40 mg/kg; on gestation day 7.5) decreases glycinamide ribonucleotide formyl transferase (GARFT) activity and Changes of ATP, GTP, dATP and dGTP levels[1].
Lometrexol (i.p.; 40 mg/kg; on gestation day 7.5) induces abnormal proliferation and apoptosis exist in neural tube defects (NTDs)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (7-8 week, 18-20 g)[1]
-
Dosage:15, 30, 35, 40, 45 and 60 mg/kg
-
Administration:Intraperitoneal injection; on gestation day 7.5
-
Result:Increased the rate of embryonic resorption and growth retardation in a dose-dependent manner.
-
Animal Model:C57BL/6 mice (7-8 week, 18-20 g)[1]
-
Dosage:40 mg/kg
-
Administration:Intraperitoneal injection; on gestation day 7.5, for 0, 6, 24, 48 and 96 hours
-
Result:Inhibited glycinamide ribonucleotide formyl transferase (GARFT) activity and GARFT activity was maximally inhibited after at 6 hours.
Decreased the levels of ATP, GTP, dATP, and dGTP of NTDs embryonic brain tissue significantly at 6 hours.
-
Animal Model:C57BL/6 mice (7-8 week, 18-20 g)[1]
-
Dosage:40 mg/kg
-
Administration:Intraperitoneal injection; on gestation day 7.5, for 4 days
-
Result:Decreased the expression of proliferation-related genes (Pcna, Foxg1 and Ptch1) and increased the expression of apoptosis-related genes (Bax, Casp8 and Casp9) in NTD groups.
Chemical Information
-
CAS. Nr. 106400-81-1
-
Appearance Solid
-
Molecular Weight 443.45
-
Formel C21H25N5O6
-
Color White to light yellow
-
SMILES
O=C1C2=C(NC[C@H](CCC3=CC=C(C(N[C@@H](CCC(O)=O)C(O)=O)=O)C=C3)C2)N=C(N)N1
-
Synonyms
DDATHF
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Nature
2026 Jul;655(8125):1300-1308. PMID: 42457960 -
Nat Commun
Identification of purine biosynthesis as an NADH-sensing pathway to mediate energy stress. [Abstract]2022 Nov 17;13(1):7031. PMID: 36396642
Lometrexol purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Nov 17;13(1):7031. [Abstract]
Effects of purine biosynthesis inhibitors on proliferation of HeLaTet-on EcSTH cells (n = 3 biologically independent samples). Cells were pretreated with the indicated inhibitors for 2 h and counted after treatment with Dox (1 µg/mL) and inhibitors for 48 h. 6-Mercaptopurine (6-MP, 300 µM), pelitrexol (PTrexol, 10 µM), Lometrexol (LTrexol, 10 µM).
-
Sci Signal
Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer. [Abstract]2024 Nov 26;17(864):eadp1375. PMID: 39591412
Lometrexol purchased from MedChemExpress. Usage Cited in: Sci Signal. 2024 Nov 26;17(864):eadp1375. [Abstract]
Measurements of cell death of 22Rv1 WT and GCN2 KO cells cultured in RPMI or MEM and treated with vehicle or Lometrexol (1 µM) for 6 days.
-
-
-
-
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (225.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
Reinheit & Dokumentation
-
Data Sheet (278 KB)
-
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Xu L, et, al. The effect of inhibiting glycinamide ribonucleotide formyl transferase on the development of neural tube in mice. Nutr Metab (Lond). 2016 Aug 23;13(1):56. [Content Brief]
[2]. Scaletti E, et, al. Structural basis of inhibition of the human serine hydroxymethyltransferase SHMT2 by antifolate drugs. FEBS Lett. 2019 Jul;593(14):1863-1873. [Content Brief]
[3]. Bronder JL, et, al. Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function. Cancer Res. 2002 Sep 15;62(18):5236-41. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2550 mL | 11.2752 mL | 22.5505 mL | 56.3761 mL |
| 5 mM | 0.4510 mL | 2.2550 mL | 4.5101 mL | 11.2752 mL | |
| 10 mM | 0.2255 mL | 1.1275 mL | 2.2550 mL | 5.6376 mL | |
| 15 mM | 0.1503 mL | 0.7517 mL | 1.5034 mL | 3.7584 mL | |
| 20 mM | 0.1128 mL | 0.5638 mL | 1.1275 mL | 2.8188 mL | |
| 25 mM | 0.0902 mL | 0.4510 mL | 0.9020 mL | 2.2550 mL | |
| 30 mM | 0.0752 mL | 0.3758 mL | 0.7517 mL | 1.8792 mL | |
| 40 mM | 0.0564 mL | 0.2819 mL | 0.5638 mL | 1.4094 mL | |
| 50 mM | 0.0451 mL | 0.2255 mL | 0.4510 mL | 1.1275 mL | |
| 60 mM | 0.0376 mL | 0.1879 mL | 0.3758 mL | 0.9396 mL | |
| 80 mM | 0.0282 mL | 0.1409 mL | 0.2819 mL | 0.7047 mL | |
| 100 mM | 0.0226 mL | 0.1128 mL | 0.2255 mL | 0.5638 mL |